menu
    • menu
    [{"orgOrder":0,"company":"Deverra Therapeutics","sponsor":"Coeptis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Acquisition","leadProduct":"DVX201","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Deverra Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Deverra Therapeutics \/ Coeptis Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Deverra Therapeutics \/ Coeptis Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Deverra Therapeutics

    Menu

    Deverra Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Deverra Therapeutics

                            U.S.A arrow
                            ISPOR Europe 2025
                            Not Confirmed

                            Deverra Therapeutics

                            U.S.A arrow
                            ISPOR Europe 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DVX201

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Coeptis Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Coeptis Therapeutics Signs Agreement to Acquire Allogeneic Immuno-Oncology NK Platform in Phase 1 Clinical Tri...

                            Details : Coeptis will get exclusive rights to two FDA approved IND applications and two phase 1 clinical trials investigating infusion of DVX201, an unmodified natural killer (NK) cell therapy generated from pooled donor CD34+ cells, in hematologic malignancies a...

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            April 18, 2023

                            Lead Product(s) : DVX201

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Coeptis Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth